Twitter Beğeni Hilesi

🧵2/ SABR is a novel treatment for primary #kidneycancer which is non-invasive and has fewer technical limitations than thermal ablation. We tested SABR in a 🦘&🌷phase II trial for primary RCC that was inoperable or high-risk for surgery. The benchmark was 90% control at 1-year.

Diligently conducted trial demonstrating #radiotherapy can be a safe & effective tx option for inoperable primary #kidneycancer. Having options matters to #cancer pts - and to all who care for them, regardless of specialty

The future of medicine & #radonc is brighter knowing these 2 superstars are in it 👏

ASTRO’s statement in support of patients and communities affected by the conflict in Israel:

Communities are key to achieving shared goals, regardless of our backgrounds & identities. It’s a privilege to be part of this one. #PCF #HealthEquity UroToday.com

Many agree critical questions remain re: clinical value of treating #ProstateCancer seen only on PET. So let’s get some answers & prove that our treatments help #patients more than they hurt ZERO Prostate Cancer UroToday.com

The ASCO elections are OPEN!! Please take time to help us select the next leaders for this incredible organization! And congrats to Dr. Small - we are in great hands! Conquer Cancer, the ASCO Foundation Sumanta K. Pal, MD, FASCO Robin Zon, MD, FACP, FASCO Eric Winer, MD Cardinale B. Smith Neha Vapiwala Nathan A. Pennell MD, PhD, FASCO brnw.ch/21wE3KK

Excited for this collaboration with Zeke Emanuel Neha Vapiwala Mendel.ai testing a Human + NLP collaborative platform to improve the efficiency of eligibility assessment in #clinicaltrials. Penn Medicine - Abramson Cancer Center Penn Cancer Innovation

Meet some of the esteemed chairs of #APCCC24, driving forward the conversation in advanced #prostatecancer. Connect with the forefront of oncology leadership. Visit now: apccc.org/apccc-2024/sci… #OncologyLeaders aurelius omlin silke gillessen Derya Tilki, MD Neha Vapiwala neal shore

Truly enjoyed chatting w UroToday re this nationwide trial seeking to help us & our #ProstateCancer pts understand the clinical benefit of #PET-directed treatment intensification. Trying to put the horse back before the cart! National Cancer Institute JanssenUS Blue Earth Diagnostics

You may be eligible to participate in a #prostatecancer study, EA8191/INDICATE, for patients with post-prostatectomy recurrence. Learn more: bit.ly/ea8191indicate #pcsm #ProstateCancerAware cc: @nehavapiwala

Huge shoutout 🙌🏽 to all sites contributing to phase III INDICATE trial investigating clinical value of SBRT for PET-detected metastases in #ProstateCancer - our #patients deserve to know! Penn Medicine Fox Chase Cancer Center UT Southwestern Medical Center UPMC Hillman Cancer Center WashU VCU Massey Comprehensive Cancer Center UW Health | Carbone Cancer Center

Thrilled to be part of Penn Medicine Penn Medicine - Abramson Cancer Center Penn Medicine MD at ASCO #ASCO24 with amazing leadership from Robin Zon, MD, FACP, FASCO and Angie DeMichele, MD, MSCE, FASCO Neha Vapiwala Ravi B. Parikh Melina Marmarelis Ronac Mamtani Lova Sun Corey Langer

Churchill said, "We make a living by what we get, but we make a life by what we give.” Thank you to these 3 incredible colleagues for exemplifying the spirit of these words in their actions - congrats! 🙌🏽

Grateful for colleagues Women in Oncology & Healio who serve the entire #cancer community, increasing awareness of safe & effective treatments like #radiationtherapy. Through greater awareness comes greater #patient access. ASCO Jill Feldman